Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insider Analysis From L.E.K Consulting On Expanding in China’s Medtech Market (Part 2 of 3)

This article was originally published in PharmAsia News

Executive Summary

Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for multinational device makers.

You may also be interested in...



Insider Analysis From L.E.K Consulting On Expanding In China’s Medtech Market (Part 3 of 3)

Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for multinational device makers.

Insider Analysis From L.E.K Consulting On Expanding In China’s Medtech Market (Part 1 of 3)

Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for device makers wanting to enter China.

Insider Analysis From LEK On Tackling China’s EDL Challenge: Navigating The Changes And Planning For Success

After a review of the newly listed products on China’s Essential Drug List, LEK believes price declines and market access can be managed and continued growth is possible for originator products added to the EDL.

Topics

UsernamePublicRestriction

Register

SC084623

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel